We Claim:

1. A sustained release dosage form comprising oxybutynin for use in managing the plasma concentration of oxybutynin and dry mouth associated with the use of oxybutynin, wherein the sustained dosage form upon once daily administration is characterized by the sustained release of a therapeutically effective dose of oxybutynin to a patient responsive to oxybutynin for managing the plasma concentration and dry mouth associated therewith.

2. The sustained release dosage form according to claim 1, wherein the plasma concentration is proportional to the sustained release dose.

3. The sustained release dosage form according to claim 1, wherein the sustained release dosage form releases up to 25 mg per hour of oxybutynin, or oxybutynin therapeutically acceptable salt.

4. The sustained release dosage form according to claim 1, wherein the sustained release dosage form comprises up to 650 mg of oxybutynin, or oxybutynin therapeutically acceptable salt.

5. A sustained release dosage form comprising oxybutynin an pharmaceutically acceptable carrier for managing dry mouth associated with oxybutynin, wherein the sustained release dosage form upon once daily use is characterized by a sustained release therapeutically effective dose up to 25 mg per hour to a patient responsive to oxybutynin therapy to provide a plasma concentration proportional to the sustained release dose for managing dry mouth.

6. Oxybutynin for use in providing a sustained release dosage form comprising oxybutynin and a pharmaceutically acceptable carrier, wherein the sustained release dosage form is characterized by comprising up to 650 mg of oxybutynin and up to 450 mg of a pharmaceutically acceptable carrier for releasing up to 25 mg per hour of oxybutynin to an oxybutynin receptive environment.

7. A method for managing dry-mouth in a patent administered oxybutynin, wherein the method comprises orally administering to the patient a sustained release dosage form comprising an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that administers the oxybutynin in a controlled rate over twenty-four hours for managing dry mouth in a patient.

8. A method for managing dry mouth in a patient administered oxybutynin for the management of incontinence, wherein the method comprises administering a sustained-release dose of 5 mg to 30 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt up to twenty-four hours for managing dry mouth in the patient.

9. A method for relaxing bladder muscles and for managing concomitantly dry mouth in a patient administered oxybutynin hydrochloride, wherein the method comprises administering 5 mg to 30 mg of oxybutynin hydrochloride in a sustained rate up to twenty-four hours for producing the intended effect.

10. A method for decreasing the incidence of dry-mouth in a patient administered oxybutynin, wherein the method comprises orally administering

to the patient a sustained-release dosage form comprising an oxybutynin selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt, that administers the oxybutynin in a controlled rate over twenty-four hours for decreasing the incidence of dry-mouth in the patient.

11. A method for decreasing dry-mouth in a patient administered oxybutynin for the management of incontinence, wherein the method comprises administering a sustained-release dose of 5 mg to 30 mg of a member selected from the group consisting of oxybutynin and its pharmaceutically acceptable salt up to twenty-four hours for decreasing dry-mouth in the patient.

12. A method for relaxing bladder muscles and for decreasing concomitantly dry-mouth in a patient administered oxybutynin hydrochloride, wherein the method comprises administering 5 mg to 30 mg of oxybutynin hydrochloride in a sustained-rate up to twenty-four hours for producing the intended effects.

13. The use of a sustained release dosage form in the manufacture of once daily oxybutynin therapy and the management of dry mouth associated therewith, which manufacture comprises the incorporation into a sustained release dosage form adapted for once daily admittance into an environment of use for oxybutynin therapy and concomitantly dry mouth associated therewith.

14. The use of oxybutynin in the manufacture of a sustained release dosage form indicated for oxybutynin therapy and for the management of dry mouth associated therewith, the manufacture comprising the step of incorporating oxybutynin into a sustained release dosage form, which when

admitted daily into an environment of use release oxybutynin and provides management of dry mouth associated therewith.